Investigating how the Crk protein affects immune cell responses
The adaptor protein Crk in immune responses
This study is looking at how a protein called Crk helps control the activity of important immune cells, like NK cells and T cells, to better understand how we can boost the immune response in people with certain cancers, especially triple negative breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11045665 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the Crk adaptor protein in regulating the activation and inhibition of natural killer (NK) cells and T cells, which are crucial components of the immune system. By utilizing advanced imaging techniques and human primary cell assays, the study aims to uncover how Crk influences immune responses, particularly in the context of cancer. The researchers will also explore new small molecule inhibitors that could potentially enhance immune function in patients with certain cancers, such as triple negative breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with immune deficiencies or those diagnosed with triple negative breast cancer.
Not a fit: Patients with conditions unrelated to immune response or those not affected by the specific cancers being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance immune responses in cancer patients, improving treatment outcomes.
How similar studies have performed: Previous research has shown promising results in targeting immune regulatory proteins, suggesting potential for success in this novel approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Liu, Dongfang — Rutgers Biomedical and Health Sciences
- Study coordinator: Liu, Dongfang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.